Biogen to present Empaveli long-term data at ASN Kidney Week

October 19, 2026 7:30 AM

Biogen Inc. (Nasdaq: BIIB) will present new data from its nephrology portfolio, including 76-week results for its approved therapy Empaveli ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found